Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- diabetes -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (44)	10/7/2002 11:49:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 278

Japan Tobacco's decision to end the drug's development follows....... Nippon Rinsho 2001 Nov;59(11):2207-10 [The chemical structure and pharmacological properties of a novel isoxazolidinedione insulin sensitizer, JTT-501] [Article in Japanese] Shinkai H. Central Pharmaceutical Research Institute, Japan Tobacco Inc. JTT-501 is an isoxazolidine-3,5-dione derivative. This drug activates both PPAR gamma and PPAR alpha, and shows not only a hypoglycemic effect but also a stronger triglyceride-lowering effect than the thiazolidine-2,4-diones. JTT-501 improved both the impaired insulin-stimulated autophosphorylation levels of Zucker fatty rats and impaired insulin-induced GLUT4 translocation to the plasma membrane as well as insulin-induced glucose uptake in high fat diet rats, indicating that JTT-501 enhances insulin signaling and reduces insulin resistance. Furthermore, JTT-501 prevented several diabetic complications, such as cataract, nephropathy, and neuropathy in Zucker diabetic fatty rats. As a non-thiazolidinedione insulin sensitizer, JTT-501 has been the first to start clinical trials and is currently undergoing evaluation in clinical studies for diabetic patients.